肝病患者血浆MMP-3、TIMP-1、u-PA和u-PAR水平的临床研究  

Clinical analysis of plasma MMP-3,TIMP-1,u-PA and u-PAR in patients with hepatic cirrhosis or hepatocellular carcinoma

作　　者：张虹[1] 周欢琴[1] 翁秀妹[1] 卢兴国[2] 朱杰[1] 

机构地区：[1]浙江医院消化内科,杭州310013 [2]浙江大学附属二院血液科,杭州310007

出　　处：《中国卫生检验杂志》2010年第1期107-109,共3页Chinese Journal of Health Laboratory Technology

基　　金：浙江省医药卫生科学研究基金立项项目(2007B016)

摘　　要：目的:探讨乙型肝炎后肝硬化和肝癌患者血浆基质金属蛋白酶3(MMP-3)、基质金属蛋白酶抑制剂-1(TIMP-1)、尿激酶型纤溶酶原激活物(u-PA)及其受体(u-PAR)的水平变化及其临床意义。方法:应用酶联免疫吸附试验(ELISA)测定血浆MMP-3、TIMP-1、uPA和u-PAR的水平。结果:①与正常对照组比较,肝硬化患者代偿期组血浆MMP-3和u-PAR水平升高,差别有显著性(P<0.01);肝硬化患者失代偿期组血浆u-PA、u-PAR、TIMP-1水平和TIMP-1/MMP-3比值均明显升高,差异有显著性(P<0.01和P<0.05);肝癌患者血浆u-PA和u-PAR水平显著升高(P<0.01),约是对照组的两倍,TIMP-1和TIMP-1/MMP-3比值水平亦明显升高,差异有显著性(P<0.01)。②肝硬化患者失代偿期组与代偿期组比较血浆u-PA、u-PAR和MMP-3水平均明显增高,TIMP-1/MMP-3比值亦明显增高,差异均有显著性(P<0.01)。③肝癌组与肝硬化患者代偿期组比较血浆u-PA、u-PAR、MMP-3、TIMP-1水平和TIMP-1/MMP-3比值均明显增高,差异均有显著性(P<0.01);肝癌组与肝硬化失代偿期组比较血浆u-PA、u-PAR和MMP-3水平均无显著性差异(P>0.05),而血浆TIMP-1水平和TIMP-1/MMP-3比值明显增高,差异有显著性(P<0.01)。结论:乙型肝炎后肝硬化和肝癌患者血浆MMP-3、TIMP-1、u-PA和u-PAR水平变化与疾病的病理进程有密切相关。Objective：To investigate the clinical significance of plasma matrix metalloproteinases-3（MMP-3）,tissue inhibitor of metal protease-1（TIMP-1）,urokinase type plasminogen activator（u-PA） and urokinase type plasminogen activator receptor（u-PAR） in hepatitis B patients with heurokinase type plasminogen activatorpatic cirrhosis or hepatocellular carcinoma（HCC）.Methods：Plasma MMP-3,TIMP-1,u-PA and u-PAR were measured by ELISA kits.Results：① In compensated hepatic cirrhosis patients,plasma MMP-3 and u-PAR were significantly higher than in healthy controls（P〈0.05 and P〈0.01,respectively）;In decompensated hepatic cirrhosis patients,plasma TIMP-1,and the ratio of TIMP-1/MMP-3 were significantly higher（P〈0.01）;Plasma u-PA and u-PAR in patients with HCC were about twice of that in healthy controls（P〈0.01）,the ratio of TIMP-1/MMP-3 and the level of plasma TIMP-1 were also significantly higher（P〈0.01）;② Compared with compensated hepatic cirrhosis patients,plasma u-PA,u-PAR and the ratio of TIMP-1/MMP-3 were significantly higher in patients with decompensated hepatic cirrhosis（P〈0.01）;③ Compared with compensated hepatic cirrhosis patients,plasma u-PA,u-PAR,MMP-3,TIMP-1 and ratio of TIMP-1/MMP-3 were significantly increased in HCC group（P〈0.01）.No difference was found between decompensated hepatic cirrhosis patients and HCC patients in plasma MMP-3,TIMP-1,u-PA and u-PAR（P〉0.05）,but the ratio of TIMP-1/MMP-3 was significantly increased in HCC group（P〈0.05）.Conclusion：The changes of plasma MMP-3,TIMP-1,u-PA and u-PAR are closely related to pathologic progression in hepatitis B patients with hepatic cirrhosis or hepatocellular carcinoma.

关 键 词：肝硬化 肝癌 MMP-3 TIMP-1 U-PA U-PAR 

分 类 号：R573[医药卫生—消化系统]